Genomic Solutions Opens New Proteomic Center
ANN ARBOR, Mich., Sept. 21 /PRNewswire/ -- Genomic
Solutions Inc. (Nasdaq: GNSL), a leading, worldwide supplier
of automated solutions for genomic and proteomic research,
announces the opening of its new, state-of- the-art Proteomic
Center located at the Ann Arbor headquarters.
(Photo:
newscom.com
)
The Proteomic Center's research and development, contract
research services and reagent manufacturing labs are currently
operative and supplying products and services to customers
around the world. GSI has hired skilled personnel with the
experience required to offer high quality in-house proteomic
research services from customer project planning to full
protein characterization. The lab has the capacity to run
hundreds of large format 2-D gels per week and identify and
characterize thousands of proteins. Tools used include several
methods of prefractionation followed by either 1-D or large
format 2D gel electrophoresis with both IEF and IPG first
dimension. Following separation, the entire automated
Investigator Proteomic System for gel staining, imaging,
analysis, plug excision, digestion and spotting to MALDI targets
is used to provide maximum throughput and reproducibility. A
full complement of Mass Spectrometers is used including ion
trap MS, MALDI-TOF MS and LC-MS/MS for protein
characterization, identification and de-novo sequencing {in gel
sequencing}.
"The business is growing rapidly, and now our new Proteomic
Center provides us with the state of the art infrastructure and
highly skilled personnel we will require to sustain our growth,"
says Christine Ethier, Vice President of the Proteomics Business
Unit at Genomic Solutions. "Our goal is to be the premier
proteomic automation company and fee-for-service protein
characterization laboratory in the marketplace. We have made
a major investment in the infrastructure required to
accomplish this including a more than doubling of our staff of
highly recruited scientists." To that end, Genomic Solutions has
announced the following appointments within its Proteomics
Business Unit:
Michael Pisano, Ph.D., recently joined Genomic Solutions as
Vice President of Proteomic Research and Development. Dr.
Pisano comes to GSI from Aventis Pharmaceuticals where he
was head of the Protein Sciences Group. The Group was
responsible for proteomic projects within the company as well
as development and implementation of proteomic
technologies.
Beth Allen, Ph.D., has joined Genomic Solutions as Director of
Proteomic Research Services. She is responsible for operation
of the Proteomic Research Service Laboratory. Dr. Allen
played a key role in the initiation and implementation of a
proteomic facility at Los Alamos National Laboratories.
Rick Edmondson, Ph.D., has joined Genomic Solutions as
Director of the Protein Mass Spectrometry Group. Dr.
Edmondson was previously responsible for the mass
spectrometry portion of the Protein Sciences group at Aventis
Pharmaceuticals. He is now responsible for the operations of
the Protein Mass Spectrometry Group in Proteomic R&D.
In addition, the Proteomic Center is staffed with several other
Ph.D. and bachelor level staff scientists and technicians
recruited from academia and industry.
"We now have the most sophisticated proteomic instruments
available, plus the experienced people to operate them," Dr.
Pisano notes.
"The Proteomic Center offers a unique situation in which we
provide research services on a contractual basis and, if so
desired, the technology and products can actually be
transferred to the customer. This also allows the development
of proteomic technologies to be driven by the needs of
researchers with whom we will be involved on a daily basis,"
Dr. Pisano adds.
Genomic Solutions Inc. designs, develops, manufactures,
markets and sells instruments, software, consumables and
services used to determine the activity level of genes and to
isolate, identify and characterize proteins. The company's
products and systems enable researchers to perform complex,
high volume experiments at a lower cost and in less time than
traditional techniques. As a result, Genomic Solutions products
and systems facilitate more rapid and less expensive drug
discovery. Genomic Solutions markets products through its
corporate headquarters in Ann Arbor, Michigan USA, and
offices in the United Kingdom and Japan. Remaining worldwide
distribution is provided by PerkinElmer Life Sciences through a
strategic alliance with Genomic Solutions. The two companies
also cooperate to sell co-branded products and collaborate to
leverage their intellectual property and technologies.
corporate-ir.net ir_site.zhtml?ticker=gnsl&script=410&layout=7&item_id=118282 |
